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Plants are valuable sources of medicinal compounds and their use for healing is 
well known from ancient times. Natural drugs obtained from plants represent about 25% 
of the prescription drug market in the United States. Plants have a long history of use in 
the treatment of various cancer types. Currently, 60% of the anticancer agents available 
in the market are derived from natural sources. Since phytoconstituents play a vital role 
in the discovery of various anticancer drugs, they have been chosen as the area of focus 
for our research. In this proposed study, four medicinal plants with reported anticancer 
activity were selected (Hydrastis canadensis, Curcuma longa, Zingiber officinalis, and 
Alpinia officinarum). All these plants were extracted by percolation and tested for anti-
proliferative activity against Dictyostelium cells. C. longa, Z. officinalis and A. 
officinarum organic extracts all showed significant anti-proliferative activity in this 
preliminary bioassay. Of the three active extracts, the turmeric extract was chosen for 
further investigation because of its great historical significance and the promising results 
of recent phase I clinical trials. Using flash chromatography, a total of nine fractions were 
obtained from the complex C. longa organic extract. Curcumin in these fractions was 
identified and quantified using high performance liquid chromatography – electrospray 
ionization mass spectrometry (HPLC-ESI-MS). Other active components 
(demethoxycurcumin, bisdemethoxycurcumin and ar-tumerone) were also characterized 
using the same system. All these fractions were then tested for in vitro anti-proliferative 
activity against MCF-7 cells using the XTT assay to determine whether activity correlates 
with the presence of curcumin in the fractions, or whether other (perhaps unidentified) 
compounds are involved. The results indicated that the major component curcumin was 
responsible for the majority of the anti-proliferative activity of the complex turmeric 
extract. Although no synergistic activity was seen for the various constituents present in 
the complex extract in this case, a novel approach for probing potential synergistic or 
additive effects was demonstrated. This approach could be applied to future 
investigations of synergistic or additive activity of medicinal plants.   
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CHAPTER I 
INTRODUCTION AND RESEARCH GOALS 
 
 
1.1 Natural products and their role in cancer treatment 
 
Natural products are valuable sources of medicinal compounds and their use for 
healing is well known from ancient times. They still continue to provide new remedies to 
human kind in treating various diseases. Though significant development has been made 
in the combinatorial chemistry field, drugs derived from natural products still play an 
important role in the drug discovery process
1
. Today, natural drugs obtained from plants 
still represent about 25% of the prescription drug market in the United States
2
. 
Furthermore, according to the World Health Organization, 80% of the population in 
developing countries depends on traditional medicine for their primary health care, and 
85% of traditional medicine is derived from plant extracts
2
.  
Cancer, a dreadful disease, is considered to be a leading cause of death in the 
United States, second only to heart disease
3
. Over the past 25 years, the United States 
government, through the National Cancer Institute (NCI), has expended billions of 
dollars to combat cancer
2
. In the process of development of drugs to treat cancer, natural 
products played an important role as contemporary cancer chemotherapeutic agents. 
Plants have a long history of use in the treatment of various cancer types
4
. Natural 
product chemists collect plants throughout the world, prepare their extracts and subject 
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them to various biological screening processes, which finally lead to the isolation and 
characterization of active compounds. Over 35,000 plant samples had been collected 
world wide by the National Cancer Institute (Natural Products Branch) and had screened 
around 114,000 extracts for antitumor activity
5
. As a consequence of extensive research, 
a number of clinically useful and market approved drugs are now available for use. It is a 
known fact that 60% of currently used anticancer agents are derived from natural 
sources
6
. Since plant constituents constitute an important source of cancer drugs, they 
have been chosen as the area of focus for this research. 
 
1.2 Selection of medicinal plants 
In this study, the first step was to select the medicinal plants which were shown to 
possess anticancer activity. To date, over 3000 species of plants had been reported to 
possess anticancer properties
7
. So, correct choice of plant material was necessary. Hence, 
in order to narrow the list of plants the following factors were considered: 
• Plants that showed success with in vitro and/or in vivo studies 
• Plants whose exact mechanism of action was not fully understood 
• Plants that are native to North Carolina 
Finally, four plants were selected and subsequently obtained to begin the 
preliminary research. Of these chosen plants, goldenseal is the only plant native to North 
Carolina. 
1) Goldenseal (Hydrastis canadensis) – Rhizome 
2) Turmeric (Curcuma longa) – Rhizome 
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3) Ginger (Zingiber officinalis) – Rhizome 
4) Lesser galangal (Alpinia officinarum) – Rhizome  
Of all the plants selected, turmeric, ginger and lesser galangal extract all showed 
activity in our preliminary bioassay.  Of the three active extracts, the turmeric extract was 
chosen for more detailed studies given its traditional and clinical significance
8, 9
. 
Turmeric (Curcuma longa) has been used for thousands of years as a healing agent for 
variety of illnesses. Turmeric was found to be a vital source of active components that 
have strong anti-inflammatory and anticancer activities, including most notably the 
compound curcumin
10
. Based on several research studies, curcumin can be considered as 
a promising tool for cancer therapy and also has undergone a number of phase I human 
trials
11
. Although several cellular and molecular mechanisms of action for curcumin have 
been proposed the precise mode of anti-proliferative activity of curcumin has not been 
fully elucidated
12, 13
. Since turmeric extract is a mixture of several components, it is of 
interest to study how the presence of these multiple components affects the overall anti-
proliferative activity of the complex turmeric extract. Taking all these facts into 
consideration, the turmeric plant was chosen as the plant of focus for this research. 
 
1.3 Curcuma longa (Turmeric) 
Curcuma longa or turmeric, a perennial herb belonging to ginger family, is a 
tropical plant native to southern and southeastern tropical Asia.  The rhizome part of the 
turmeric plant is considered to be the main source of active components. The dried 
rhizome of turmeric contains the flavonoids curcumin, demethoxycurcumin and 
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bisdemethoxycurcumin, which are commonly known as curcuminoids, as well as volatile 
oils (mostly terpenoids) such as tumerones, atlantones and zingiberene
14, 15
 (Figures 
1&2). The most extensively studied component is curcumin (diferuloylmethane) which 
comprises 2-5% of the total components in turmeric. Over 2000 papers have been 
published on turmeric over the last 50 years
16
.   
Curcumin possess various biological activities like anti oxidant, anti inflammatory, 
anti platelet, anti viral, anti fungal, and anti bacterial activities and also has been used in 
the treatment of Alzheimer’s disease, multiple sclerosis and rheumatoid arthritis. 
Moreover, there is extensive literature which indicates the potential of curcumin in the 
prevention and treatment of various cancers
7
. Of all the curcuminoids, curcumin was 
found to possess the most potent anti-proliferative activity (e.g. human ovarian cancer 
cell line Ho-8910 inhibition by MTT assay
17
). In one study, it was shown that 
demethoxycurcumin is a better anti-proliferative agent than the other two curcuminoids 
(MCF-7 human breast cancer cell line inhibition
18
). Bisdemethoxycurcumin also showed 
more significant cytotoxic activity than the other two 
19
. It was also found that all three 
curcuminoids exhibited similar anti-proliferative activity against various cell lines 
(Jurkat, KBM-5, and A549 cell lines
16
). Among the volatile oils, ar-tumerone exhibited 
potent cytotoxic effect on cancer cell lines like K562, L1210, U937 and RBL-2H3 by 
MTT assay
20
.  
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Fig 1 - Structures of curcuminoids found in turmeric extract 
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Fig 2- Structures of main volatile oil components present in Turmeric oil 
 
 
 
1.4 Anticancer activity of curcumin in vitro 
Curcumin, an active constituent of C. longa extract, has the ability to induce 
apoptosis in different cancer cells. This property was used in developing curcumin as a 
universal cancer prophylactic agent
21
. Curcumin has been shown to suppress 
transformation, proliferation and metastasis of tumors through various mediators like 
transcription factors, growth factors, growth factor receptors, inflammatory cytokines, 
protein kinases, various enzymes and genes regulating apoptosis and proliferation
22
. It 
also inhibits proliferation of cancer cells by arresting them in various phases of the cell 
O
OH
Ar-tumerone 
MW-216 
 
α -tumerone 
MW-218 
 
β -tumerone 
MW-218 
 
Curlone 
MW-218 
 
Curcumene 
MW-202 
 
α-tumerol 
MW-218 
 
O
H
O
O
H
  
 7 
cycle and by inducing apoptosis, indicating its potential in the treatment of various 
cancers. In vitro studies conducted on curcumin have shown to inhibit the growth of large 
number of human cancer cell lines, like leukemia, prostate, lung, renal, colon, melanoma, 
breast
23
, hepatocellular and ovarian carcinomas.   
 
1.5 Methods used for the analysis of Turmeric extract 
The main aims of natural product research are - qualitative and quantitative analysis 
of medicinal plant constituents and isolation of biologically active purified plant extract 
fractions or compounds. So, considering the fact that a single plant can have several 
thousand constituents, the above goals can be achieved by employing rapid and high 
performance separation methods. A major task for a phytochemist in the analysis of 
natural compounds is the characterization of compounds with minimal sample 
preparation. Usually compounds present in the plant extracts can be separated rapidly 
using chromatography. A liquid chromatographic method with spectrophotometric 
detection was developed for the first time in 1953 to separate and quantify 
curcuminoids
24
. Later on, various methods such as paper or thin layer chromatography
25, 
26
 (TLC), capillary electrophoresis
27
 (CE), gas chromatography
28
 (GC), high performance 
liquid chromatography (HPLC), and its coupling to photodiode array detection (HPLC-
DAD
29
) and mass spectrometry (LC-MS
30
) were used to analyze the chemical 
constituents of turmeric extracts. Xian-Guo He et al. (1998) were the first researchers to 
employ online high performance liquid chromatography-electro spray ionization-mass 
spectrometry (HPLC-ESI-MS) for the identification of turmeric constituents
30
. Not only 
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individual curcuminoids but also a number of essential oil constituents like ar-tumerone 
and curlone could be identified from a single HPLC analysis. Hongliang Jiang et 
al.(2006) and Kuo-Yi Yang et al.(2007) validated HPLC coupled with tandem mass 
spectrometry (LC-MS/MS) to identify curcuminoids in turmeric extract
31, 32
.  
The aroma of turmeric is due to the presence of several volatile oils. These volatile 
oils are usually a mixture of sesquiterpene ketones and alcohols. Malingre (1975) for the 
first time reported volatile oil constituents’ ar-tumerone, tumerone, curlone, curcumene 
and other sesquiterpene alcohols from Curcuma longa
33
. Phan et al. (1987) for the first 
time reported the GC-MS analysis of turmeric oil
34
. Richard Hiserodt et al. (1996) 
employed direct thermal desorption-gas chromatography-mass spectrometry (DTD-GC-
MS) for the analysis of various volatile and semi-volatile compounds in powdered 
turmeric
35
. GC-MS serves as a convenient and sensitive analytical technique for 
analyzing essential oils, and remains one of the most common methods applied for this 
purpose. And also online HPLC-ESI-MS technique was used to analyze various 
sesquiterpenoid volatile components present in turmeric extract
30, 35
.  
 
1.5.1 HPLC-ESI-MS 
Chromatographic separation coupled with mass spectrometric detection provides a 
pathway for the rapid and sensitive characterization of active compounds from plant 
extracts. LC-MS, which couples liquid chromatography (LC) with mass spectrometry 
(MS), has gained attention as a convenient method for identification, structural 
determination, and quantitative analysis of various bioactive compounds in complex 
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extracts. LC-MS is considered to be a major breakthrough in the analysis of natural 
products possessing significant biological activities. Of the various LC-MS techniques, 
high performance liquid chromatography coupled to electro spray ionization-mass 
spectrometry (HPLC-ESI-MS) is an ideal technique for the analysis of a wide variety of 
analytes
36
. This soft ionization technique coupled to a single quadrupole mass 
spectrometer provides the molecular weight of compounds, and further structural details 
can be obtained with HPLC-MS-MS systems (those with triple quadrupole or ion trap 
mass analyzers), which provide information on the characteristic fragmentation pattern 
typical of a compound. In contrast to other ionization techniques, multiply charged 
analytes can easily be formed with ESI, making it possible to analyze larger molecules. 
Small polar to medium polar analytes are also readily ionized with this technique, making 
HPLC-ESI-MS useful in phyto-chemical investigation
37
. In most quantitative HPLC-ESI-
MS methods, low detection limits and reproducible results are the desirable features. A 
schematic of an HPLC-ESI-MS system is shown in Figure 3. A typical HPLC-ESI-MS 
system has mainly three different regions; the HPLC system, the ESI ion source and the 
mass spectrometer. An HPLC-ESI-MS system similar to that shown in Figure 4 was 
employed for this study to analyze the plant extracts.  
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1.6 Evaluation of biological activity (Anti-proliferative activity) 
The isolation of anticancer natural products needs an appropriate bioassay to guide 
fractionation at each step. Many bioassay systems are available for anticancer drug 
discovery. A screening bioassay is applied to large number of initial samples to identify 
those with desired bioactivities. The purpose of using this bioassay is to discard inert 
materials and identify active fractions. A monitoring bioassay is used to guide 
fractionation of crude materials towards isolation of the pure active components. Modern 
analytical instrumentation may be most effective in bioassay-directed isolation.  In this 
research, Dictyostelium cells and MCF-7 human breast cancer cells have been selected to 
test for anti-proliferative activity of fractions and constituents of C. longa.  
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Fig 3 - Schematic representation of an HPLC-ESI-MS hyphenated system 
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1.6.1 Dictyostelium cells 
In this study, the initial screening of all the plants extracts was done using the 
model system Dictyostelium discoideum. Dictyostelium was used as a powerful 
eukaryotic model system for identifying and characterizing the basic mechanisms which 
control the cell division
38
, cell migration
39
, multicellular development processes
40
 and 
other vital cellular processes that play significant roles in various diseases. When 
compared to other cell types, this cell type is considered to be less complicated (i.e. easy 
to grow, handle and manipulate). Several studies on Dictyostelium have provided useful 
information on how the various cellular processes were been altered during the 
uncontrolled cell multiplication seen in tumor growth
41, 42
. This model system allows 
identifying a specific gene involved in this process and also serves as a model for 
processes that occur in mammalian cells, since it has some of the complex features that 
resemble mammalian cells. Perhaps most importantly, Dictyostelium discoideum is an 
extensively studied model organism for which a great deal of genome sequencing work 
has been completed
43
.  
 
1.6.2 MCF-7 Human breast cancer cells 
In addition to Dictyostelium cells, the MCF-7 Human breast cancer cell line was 
employed in order to identify the fractions of C. longa with significant anti-proliferative 
activity. The MCF-7 cell line, initially developed by Soule et al. (1973), was used 
universally for various in vitro and in vivo studies on potent compounds used in the 
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therapy of breast cancer as it relates to the vulnerability of the cells to apoptosis
21
. This 
cell line is the best characterized of all the existing estrogen responsive lines. Since MCF-
7 cells are mammalian cells, the data derived from these cell lines will be used as a first 
step towards gaining insight into the possible anti-tumor activity of the components of 
interest.  Follow up experiments would be necessary to confirm the in vivo relevance of 
any anti-proliferative effects observed in vitro. Curcumin has already been shown to 
suppress cell proliferation of MCF-7 human breast cancer cells by targeting several 
molecules and pathways involved in cancer pathogenesis
44, 45
.  
 
1.7 Measuring viability of cells using XTT assay 
In the process of screening various cytotoxic agents, determination of viable cell 
number is often used to measure the cell proliferation rate. The XTT assay, a colorimetric 
method, is a valuable method for screening of plant extracts for anti-proliferative activity. 
The XTT method is a simple, fast, rapid and accurate assay and yields reproducible 
results
46
. In this assay, the XTT reagent (tetrazolium salt) combines with mitochondrial 
dehydrogenase enzyme of viable cells yielding orange colored formazan crystals. The 
amount of formazan formed indicates the degree of cytotoxicity caused by the test 
samples (i.e. the amount of formazan resulted from XTT is proportional to the total 
number of living cells in the sample wells). The resulting orange colored product was 
quantified by measuring the absorbance spectrophotometrically. The percentage of cells 
surviving after the sample treatment is determined by comparing the absorbance of 
treated cells with that of the control cells. Since dead cells are unable to metabolize 
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tetrazolium salts, the colorimetric assay like XTT can be used to measure cell 
viability/cell proliferation rate. Apoptosis, normal cell death, requires metabolism of 
cells. Hence for this reason colorimetric assay (XTT), which can not measure cellular 
damage, can detect cell death only at later stages of apoptosis when the cellular 
metabolism is reduced.  
 
1.8 Research Goals 
The main objective of this study is to separate and quantify phytoconstituents from 
Curcuma longa (Turmeric) plant extract and then test the bioactivity of isolated 
compounds. Turmeric extract is a complex extract with several components which have 
significant biological activities 
16, 12 & 47
. Though significant research was done on all the 
individual components of the turmeric extract, still the relative importance of all these 
components for the overall anti-proliferative activity is not clear. It is also not known 
whether there are compounds other than curcuminoids and volatile components that are 
important in the anti-proliferative activity of C. longa. The major goal of this study is to 
address this gap in the knowledge base. The main aim of this research is to study how the 
various components present in the complex turmeric extract contribute to its anti-
proliferative activity. To accomplish this goal, isolation, identification and quantification 
of constituents from the turmeric extract will be accomplished using HPLC-ESI-MS. 
Further, preliminary screening experiments will be conducted on the plant extracts 
obtained using Dictyostelium cells to test for anti-proliferative activity. Once the complex 
turmeric extract is separated into individual fractions or compounds, these individual 
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fractions will again to be tested for anti-proliferative activity against MCF-7 human 
breast cancer cells using the XTT assay. The flow chart (Figure 4) shown below 
represents an outline of this research- 
 
 
 
 
Fig 4 – Flow chart detailing various steps involved in the research 
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CHAPTER II 
EXPERIMENTAL METHODS  
 
 
The following section gives a brief overview of the experimental procedures used in 
the research. In order to identify and quantify active components from plant extracts the 
first step would be to extract these components using a suitable extraction process. 
Percolation utilizing suitable solvents was employed to obtain a complex extract of all 
four plants- Hydrastis canadensis, Curcuma longa, Zingiber officinalis, and Alpinia 
officinarum. These extracts were analyzed using HPLC-ESI-MS to identify major 
constituents of the extracts. The anti-proliferative activity of these extracts was then 
tested using the Dictyostelium cell model. Flash chromatography was used to further 
separate the complex turmeric extract into fractions. The concentrations of the active 
components in the fractions obtained were also determined using HPLC-ESI-MS. Finally, 
the turmeric fractions were tested against MCF-7 human breast cancer cells to identify 
fractions with significant anti-proliferative activity and to correlate the HPLC-ESI-MS 
data with biological efficacy.  
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2.1 Extraction of Curcuma longa, Hydrastis canadensis, Zingiber officinalis and 
Alpinia officinarum plants 
Two crucial stages involved in the isolation of phytoconstituents are the selection of 
plant material and the procedure of extraction. This includes grinding of the plant 
material, extraction of the constituents, and concentration and drying of the extracts. In 
this research, all the medicinal plants selected were extracted by percolation, which is a 
simple maceration process. Maceration is the most commonly used preparative extraction 
method by most of the phytoanalysts
48
. Using a laboratory grinder, the dried plant 
material was ground to fine powder to create as much surface area as possible. The 
amounts of the ground plant material taken for the purpose of extraction are given in 
Table 1. 
 
 
Table 1 – Amounts of ground plant material used for extraction 
Plant  Amount of ground plant material 
Goldenseal (Hydrastis canadensis)  
[Pacific botanicals, Lot no.- 0906M-TCP] 
500g 
Turmeric (Curcuma longa) 
 [Horizon Herbs, Lot no. – 4360] 
390g 
Ginger (Zingiber officinalis)  
[Horizon Herbs, Lot no. – 4361] 
416.5g 
Lesser Galangal (Alpinia officinarum) 
 [Horizon Herbs, Lot no.- 4362] 
312g 
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2.1.1 Procedure 
The ground plant material was initially submerged in the solvent mixture of 
dichloromethane – methanol (1:1) completely. The plant material was then left in contact 
with the solvent mixture overnight and the solvent was drained off the next morning. 
Next, the extracted plant material was covered in methanol and a second extraction was 
performed in order to rinse off the residual dichloromethane (approx. 6h). Then the 
methanol solvent was removed by suction filtration. Next, the dichloromethane – 
methanol (1:1) solubles were combined with the methanol solubles and then dried by 
rotary evaporation. Finally, sufficient water was added to cover the remaining plant 
extract, making a second extract (aqueous), which was then stored at -20
◦
C. These 
procedures resulted in an organic solvent extract and aqueous extract for each of the four 
plants that could then be further analyzed using HPLC-ESI-MS and tested for bioactivity.  
 
2.2 Identification of the active components from plant extracts using HPLC-ESI-MS 
Once the final crude extracts are obtained, they have to be chemically screened for 
the presence of active constituents. The characterization of active metabolites in complex 
plant extracts requires sophisticated hyphenated techniques, which should provide good 
sensitivity and selectivity as well as structural information on the constituents of interest. 
For this study, the HPLC-ESI-MS technique was employed to identify the bioactive 
components of the plants extracted.  
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Initially, three concentrations (1mg/mL, 0.1mg/mL, and 0.01mg/mL) of both the 
organic and aqueous extracts were prepared using methanol solvent. Using a 0.2 µm 
nylon filter, all the samples prepared were filtered prior to analysis.  
 
2.2.1 Instrumentation 
Analyses were conducted using an Agilent 1100 series HPLC instrument with a 
C18 reversed phase column (Alltech, 50mm x 2.1mm, 3µm particle size) coupled with an 
ESI-ion trap mass spectrometer (LCQ Advantage, ThermoFinnigan). A 0.5µm pre-
column filter (Mac Mode Analytical) attached to the column inlet was used to remove 
any residual particulate present in the HPLC solvents or samples. A gradient elution (0-4 
min - 90% A, 4.00-30.00 min -90-0% A, 30.10-36.00 min – 90%A) was run with mobile 
phase solvents A (1% acetic acid in nanopure water) and B (HPLC grade acetonitrile) 
with a flow rate of 0.2 mL/min and injection volume of 10µL. The mass spectrometer 
was operated with a scan range of 50-2000 m/z, a capillary temperature of 275°C, and a 
sheath gas pressure of 20 (arbitrary units). Two analyses were carried out for each 
sample, one in the positive ion mode and one in the negative ion mode. The source, 
capillary, and tube lens voltages for the positive ion mode analyses were 4.5 kV, 3V and -
60V, respectively, and for the negative ion mode analyses were 4.5 kV, -10 V and -50 V, 
respectively. The total analysis time was 36 min. 
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2.3 Primary screening of plant extracts in vitro (Anti-proliferative activity) using 
Dictyostelium cells 
Once the extracts were prepared and characterized, they were initially screened for 
anti-proliferative activity using Dictyostelium cells. The purpose of this bioassay was to 
identify the crude plant extracts with significant inhibitory effects on cell growth in vitro. 
Three concentrations (2 mg/mL, 1 mg/mL and 0.5 mg/mL) of both the organic and 
aqueous extracts of all the plants were prepared using sterile technique in DMSO and 
phosphate buffered saline (PBS) solution [NaCl (81%) + KCl (2%) + Na2HPO4, dibasic 
(14%) + KH2PO4, monobasic (3%)] of pH
 
7.4. These experiments were accomplished 
under the direction of Dr. Paul Steimle and were performed by his student Erica Fields in 
the Department of Biology at the University of North Carolina, Greensboro.   
 
2.3.1 Procedure for screening with Dictyostelium  
Dictyostelium discoideum AX2 strain
49
, an axenic mutant, was used for this in vitro 
cell inhibition assay. These cells were grown to confluence in 15 cm Petri dishes 
containing HL5 culture medium and were harvested by centrifugation. These cells were 
then used to prepare 5 x10
4
 cells/mL cultures which were transferred into Falcon tubes. 
These cell cultures were then treated with different plant extract samples. All these 
cultures were grown with shaking at 185 rpm at 21°C. A positive control (lacking plant 
extract sample) for normal cell growth was also grown. All the cultures prepared 
contained 0.7% DMSO. An aliquot of each culture was removed at 24 h interval (up to 
120 h) and the cells were counted using a hemacytometer. Growth rates for different 
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cultures were then plotted as cell number versus time. The composition of the HL5 
culture medium is given below (Table 2).  
 
 
Table 2 - HL5 culture medium composition (1liter)  
1.) 5g Protease peptone 
2.) 5g Thiotone E peptone 
3.) 10g Glucose 
4.) 5g Yeast extract 
5.) 0.35g Na2HPO4. 7H2O 
6.) 0.35g KH2PO4 
 
 
 
All the ingredients were mixed to a final volume of 1 liter. The pH of the medium 
was adjusted with HCl to 6.4 - 6.6 and was then finally autoclaved.  
 
2.4 Separation and quantification of curcumin from turmeric extract 
The main goal of this experiment was to separate curcumin from the C. longa 
organic extract and further quantify the turmeric fractions containing various amounts of 
curcumin using suitable methods. All the fractions obtained must then be screened using 
a suitable assay of anti-proliferative activity. 
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2.4.1 Procedure  
Flash chromatography over silica gel (Column dimensions, 15 × 1.5 cm) was 
employed to separate the complex C. longa organic extract. Using a binary solvent 
mixture of hexane and diethyl ether, a total of nine fractions of turmeric extract was 
obtained. The fractions were run in the increasing amounts of diethyl ether (10%, 20%, 
30%, 40%, 50%, 60%, 70%, 85% and 100%). Each of the fractions obtained was 
aliquoted (1 mL) into a pre weighed centrifuge tube and the solvent was removed under 
vacuum to determine the dry weight. The dried samples were redissolved and diluted 
using methanol solvent to make three concentrations of each fraction (1mg/mL, 
0.1mg/mL and 0.01mg/mL, expressed as mg dissolved solids per mL of solvent). Similar 
samples for the original turmeric extract were also prepared. 
The concentration of curcumin present in the turmeric fractions were quantified 
using a standard of curcumin (Acros organics, New Jersey, USA). Stock solutions of this 
standard were prepared in methanol solvent at concentrations of 0.01M and 0.03M and 
then serially diluted to make standards of concentrations 1.0 × 10
-4 
M, 1.0 × 10
-5 
M, 1.0 × 
10
-6 
M, 1.0 × 10
-7 
M, 3.0 × 10
-5 
M and 3.0 × 10
-6 
M. Finally, all of the standards, along 
with the turmeric fraction samples and the original extract samples were analyzed using 
HPLC-ESI-MS method (negative ion mode scanning) with the same conditions as 
described in Section 2.2.  
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2.5 Identification and quantification of ar-tumerone in the turmeric fractions using 
HPLC-ESI-MS 
The complex turmeric extract has several volatile oil components besides 
curcuminoids. Among the volatile oil constituents, ar-tumerone, α-tumerone and β-
tumerone have been shown to induce apoptosis on various cancer cell lines
16
. Of these 
three volatile oils ar-tumerone is the major component and is the most extensively studied 
compound. So, the next step in this research would be to identify and quantify ar-
tumerone present in the turmeric fractions obtained. For this purpose HPLC-ESI-MS was 
utilized with the same parameters mentioned in Section 2.2. Three different 
concentrations (1mg/mL, 0.1mg/mL and 0.01mg/mL) of all the nine fractions including 
the original extract were made using methanol solvent. In order to quantify ar-tumerone 
present a standard ar-tumerone (Chromadex, Santa Ana, California, USA) was used. A 
stock solution of 0.01 M ar-tumerone was prepared in methanol and then serial dilutions 
of this solution were performed to prepare solutions with concentrations of 3.0 × 10
-3 
M, 
3.0 × 10
-4 
M, 3.0 × 10
-5 
M, 3.0 × 10
-6 
M and 1.0 × 10
-6 
M. All these samples prepared (the 
fractions and the standards) were then analyzed using HPLC-ESI-MS in the positive ion 
mode.  
 
2.6 Testing turmeric fractions for anti-proliferative activity against MCF-7 human 
breast cancer cells (XTT assay) 
Once the major bioactive components present in the turmeric fractions were 
identified they had to be tested for in vitro anti-proliferative activity using a suitable cell 
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proliferation assay. For this purpose, the MCF-7 human breast cancer cell line was 
selected. The anti-proliferative activity of the complex turmeric extract, the turmeric 
fractions and the standard curcumin was tested against the MCF-7 human breast cancer 
cell line using the XTT assay in a 96 well plate format
50
. The purpose of using MCF-7 
cells for this cell viability assay is that these cells are more amenable to the 96 well plate 
set up and also the results obtained from these cells should be more closely relevant to 
humans.  
The first task in this assay was to determine the LD50 (median lethal dose) for pure 
curcumin which was determined by testing different concentrations of standard curcumin 
(1µM, 3µM, 10µM, 30µM and 100µM of curcumin in 0.5% DMSO in medium) on 
MCF-7 cells. Once the LD50 of curcumin was determined, turmeric fractions including 
the original extract containing varying concentrations of curcumin were tested against 
MCF-7 cell line, with the ultimate goal of determining which constituents of the fractions 
contributed to their anti-proliferative activity.  
 
2.6.1 Preparation of Stock Solutions 
For determining the LD50 of pure curcumin a stock solution of 24,000µM (100% 
DMSO) of standard curcumin was prepared. This stock solution was further diluted with 
media (without phenol red) to make a solution of 1200µM (5% DMSO) of standard 
curcumin.  From this stock, serial dilutions were further made using media (5% DMSO) 
to make solutions of five different concentrations (1000µM, 300µM, 100µM, 30µM, and 
10µM). Finally, 20µL of each of these concentrations when present in a final well 
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volume of 200µL represents a final concentration of 100µM, 30µM, 10µM, 3µM, and 
1µM of standard curcumin (0.5% DMSO) in each well of the 96 well plate.  
Stock solutions for all the turmeric fractions (except fraction 1) including the 
original extract were prepared based on the curcumin content present in the solid extracts. 
Initially a stock solution of 7000µM (100% DMSO) of curcumin for all the turmeric 
fractions including the original extract was prepared. This stock was further diluted with 
media (without phenol red) to make a 350µM curcumin (5% DMSO) stock solution. 
From this stock solution, serial dilutions were made with media (5% DMSO) to make 
solutions of two different concentrations (300µM and 30µM of curcumin). Finally, 20µL 
of each of these concentrations in a final well volume of 200µL yields a final 
concentration of 30µM and 3µM of curcumin (0.5% DMSO). For fraction 1, which has 
only ar-tumerone but not curcumin, the stock solution was prepared based on the amount 
of ar-tumerone present in the solid extract. All these solutions were prepared under sterile 
conditions.  
 
2.6.2 Procedure 
MCF-7 human breast carcinoma cells (ATCC), grown as a monolayer in 75cm
2
 
canted neck flask (Corning), were maintained in 500 mL Dulbecco’s Modified Eagle 
Medium (DMEM) (GIBCO) supplemented with 57 mL of 10% fetal bovine serum (FBS) 
(GIBCO), 5.8 mL of 1mM sodium pyruvate (Sigma-Aldrich), 5.8 mL of 2mM L-
glutamine (Sigma-Aldrich), 5.0 mL non essential amino acids (Sigma-Aldrich), 500 µL 
insulin (Sigma-Aldrich) and 5.0 mL of 100mM penicillin/streptomycin (Sigma-Aldrich) 
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in a humidified atmosphere of 5% CO2 at 37°C. Once they have reached 70-80% 
confluence, the culture medium was removed and the adherent cells were washed with 
phosphate buffered saline (PBS, pH-7.4) (GIBCO) solution. To loosen the cells from the 
flask surface, 0.5% Trypsin-EDTA (3mL) (GIBCO) was added and was diluted with 4 
mL DMEM medium (with phenol red). From this stock culture of cells, cells of density 
1×10
5
cells/mL were prepared using DMEM medium (without phenol red) and were 
plated into each well (180µL) in a 96 well plate (Costar 3599, Corning, NY, USA). These 
cells were then incubated (at 37°C and humidified 5% CO2 atmosphere) for 2-3 days 
until they reached 70% confluence. Subsequently 20µL of each sample dissolved in 0.5% 
DMSO in medium was added to each well (in triplicate). DMSO (0.5%) was used as 
vehicle control. Wells containing cell culture medium alone, cells in medium without 
sample (negative control), and the samples in medium alone at each concentration to be 
tested (blank control) were used as additional controls. The plate was shaken using a 
rocking shaker (Lab-Line Instruments Inc, Melrose Pk, IL, USA) with a speed of 4 rpm 
to ensure that the samples were thoroughly mixed into the media. Cells were then 
incubated for 72 h at 37°C and humidified 5% CO2 atmosphere. Finally, 50µL of XTT 
reagent (Sigma Aldrich) (sodium salt of 2, 3-bis [2-methoxy-4-nitro-5-sulfophenyl]-2H-
tetrazolium-5-carboxyanilide + 1% phenazine methosulfate (PMS), 5mg in serum vial) 
dissolved in cell culture medium with out phenol red and serum (5mL) was added to each 
well of the 96 well plate and then incubated for 6 h to allow the XTT to be metabolized. 
Using a rocking shaker (speed of 4 rpm) the plate was shaken to evenly distribute the dye 
in the wells. The final volume of each well was 250µL. The XTT reagent combines with 
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the mitochondrial dehydrogenase enzyme present in the viable cells to form orange 
colored formazan crystals. The absorbance of the orange colored formazan solution in 
each well of the 96 well plate was then spectrophotometrically measured at a wavelength 
of 490nm using a plate reader (POLARstar Optima, BMG LABTECH, Durham, NC). 
The percentage of cells surviving and the concentration at which 50% of the cells remain 
viable after 72h sample treatment (LD50) were determined. Each sample was tested in 
triplicate and their mean values were taken to calculate the cell viability and LD50. Cell 
viability (%) = [(As - Ab)/Av×100] where As = Absorbance of test sample well (well with 
sample+cells+media), Ab = Absorbance of blank control well (well with sample+media 
but no cells), Av = Absorbance of vehicle control well (well with cells+DMSO of 0.5%).  
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CHAPTER III 
RESULTS AND DISCUSSION 
 
 
3.1 Extraction of medicinal plants 
The main aim of the preparative extraction method is the identification of the major 
or bioactive compound(s) from a specific plant. The concentrations (mg of dissolved 
solids per mL of solvent) of the extracts produced are shown in Table 3.  
 
 
 
Table 3- Dissolved solid extracts produced 
Plant Organic extract Aqueous extract 
Goldenseal 219mg/mL 38.7mg/mL 
Turmeric  568.8mg/mL 44mg/mL 
Ginger  13.4mg/mL 39.8mg/mL 
Lesser galangal  29.9mg/mL 25.4mg/mL 
 
 
 
These weights were obtained by transferring 1mL of extracts into eppendorf tubes 
and then drying them using a speedvac evaporator. All these extracts were transferred to 
a suitable glass container and then stored in a refrigerator (4
◦
C) for subsequent analysis. 
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3.2 Major components identified from plant extracts using HPLC-ESI-MS 
The organic and aqueous extracts of all the four medicinal plants were analyzed 
using reversed phase high performance liquid chromatography on a C18 column and 
electrospray ionization mass spectrometry method. Significant peaks were observed in 
only organic extracts and were absent in aqueous extracts.  
 
3.2.1 Analysis of Curcuma longa extract 
The base peak chromatogram of C. longa organic extract shows a significant peak 
at a retention time of 21.45 min (Figure 5). Figure 6 shows a series of selected ion 
chromatograms for different concentrations of turmeric (Curcuma longa) organic extract 
carried out in the negative ion mode. Since the phenolic group in the structure of the 
major component curcumin can be easily deprotonated, the negative ion mode scanning 
was selected. In selected ion chromatograms, ions with selected m/z values (those that 
correspond to the masses of particular components of the samples) are plotted as a 
function of time. This type of monitoring increases the selectivity for individual analytes 
and improves the detection limit by decreasing the background noise. In these 
chromatograms, an m/z value of 367 was selected since the molecular mass of neutral 
curcumin was 368. The major molecular ion present has an m/z ratio of 367 
(deprotonated curcumin) and has been identified as curcumin with reference to 
literature
30
. In addition, the retention time was found to be similar to that of the standard 
curcumin which is shown in Table 4.  
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Fig 5 – Base peak chromatogram of turmeric organic extract obtained using HPLC-ESI-
MS 
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Table 4 – Comparison of retention times of curcumin for both standard and original 
extract 
 
Curcumin  Avg. retention time Std. Dev (N= 3) 
Standard  20.63 min 0.049 
Extract  20.55 min 0.055 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 6 – Selected ion chromatogram of turmeric organic extract obtained using HPLC-
ESI-MS. Three concentrations were analyzed, a) 1mg/mL b) 0.1mg/mL and c) 0.01mg/mL 
(expressed as mg dissolved solids/mL solvent).  The m/z value of 337 was plotted, which 
corresponds to mass of deprotonated curcumin (see structure in chromatogram a.)    
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It can be concluded from the above chromatogram that the peak size increases with 
the increasing concentration of the extract (i.e. 0.01 mg/mL to 1 mg/mL), as would be 
expected.  
And also the presence of the compound curcumin was confirmed by comparing the 
MS-MS spectrum of standard curcumin with that of the peak at a retention time of 21.45 
min (Figure 7).  
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Fig 7 - Full scan mass spectra for (a) standard curcumin (molecular weight of 368) and 
(b) the peak obtained at a retention time of 21.45 min for turmeric organic extract 
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3.2.2 Analysis of Hydrastis canadensis extract 
For the analysis of goldenseal (Hydrastis  canadensis) organic extract, carried out in 
the positive ion mode scanning, the major molecular ion observed has a m/z ratio of 336 
which was been identified as berberine with reference to literature
51
. The berberine 
molecule, which has a quaternary nitrogen atom, exists as a cation. Hence the positive ion 
mode was used. A series of selected ion chromatograms for three different concentrations 
of goldenseal are shown in Figure 8. Note that without comparison to a standard, 
identification of berberine is only tentative.  
 
3.2.3 Analysis of Alpinia officinarum extract  
The major molecular ions present in the selected ion chromatograms for lesser 
galangal (Alpinia officinarum) organic extract (Figures 9, 10 and 11) have m/z ratios of 
285, 269 and 301. These ions were tentatively identified as kaempferol, galangin, and 
quercetin, respectively, with reference to literature
52
. This analysis was performed in the 
negative ion mode.   
 
Zerumbone
53
, the major component of ginger (Zingiber officinalis), could not be 
detected as a single molecular ion peak using HPLC-ESI-MS because it cannot easily be 
protonated or deprotonated. It can be analyzed using GCMS.  
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Fig 8 – Selected ion chromatogram of m/z 336 from goldenseal organic extract 
obtained using HPLC-ESI-MS for three different concentrations a) 1mg/mL b) 
0.1mg/mL c) 0.01mg/mL. The m/z value of 336 correlates with that of berberine 
(structure shown in chromatogram a.)  
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Fig 9 – Selected ion chromatogram of A. officinarum organic extract for m/z value of 
285 obtained using HPLC-ESI-MS. a) 1mg/mL b) 0.1mg/mL c) 0.01mg/mL. The m/z value 
of 285 corresponds to the mass of deprotonated kaempferol 
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Fig 10 – Selected ion chromatogram of A. officinarum organic extract for m/z value of 
269 obtained using HPLC-ESI-MS. a) 1mg/mL b) 0.1mg/mL c) 0.01mg/mL. The m/z value 
of 269 corresponds to the mass of deprotonated galangin 
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Fig 11 – Selected ion chromatogram of A. officinarum organic extract for m/z value of 
301 obtained using HPLC-ESI-MS. a) 1mg/mL b) 0.1mg/mL c) 0.01mg/mL. The m/z value 
of 301 corresponds to the mass of deprotonated quercetin 
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3.3 Anti-proliferative activity of plant extracts on Dictyostelium cells 
Organic and aqueous extracts of all the four medicinal plants were tested for anti-
proliferative activity using Dictyostelium cells. All of the aqueous extracts and the 
goldenseal organic extract showed no inhibition of cell growth. Organic extracts of 
Curcuma longa, Zingiber officinalis, and Alpinia officinarum demonstrated significant 
concentration dependent anti-proliferative activity as shown in Tables 5, 6, and 7 and 
Figures 12, 13, and 14, respectively. From the data obtained, it was found that the 
organic extracts of C. longa, A. officinarum, and Z. officinalis have shown similar anti-
proliferative activity profiles with Dictyostelium cells.  
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Table 5 – Dictyostelium cell growth in the presence of different concentrations of C. 
longa organic extract 
 
CELL NUMBER 
 
Days 
Turmeric 17 
µg/mL 
Turmeric 8.5 
µg/mL 
Turmeric 4.2 
µg/mL 
DMSO 
Control 
0 5 5 5 5 
1 6 7 9 7 
4 3 19 95 325 
5 17 7 210 400 
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Fig 12 – Effect of C. longa organic extract on Dictyostelium cell growth 
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Table 6 – Effect of different concentrations of A. officinarum organic extract on 
Dictyostelium cell count 
 
CELL NUMBER 
Days Alpinia off. 17 
µg/mL 
 
Alpinia off.8.5 
µg/mL 
 
Alpinia off.4.2 
µg/mL 
 
DMSO 
Control 
 
0 5 5 5 5 
1 4 6 11 18 
2 4 5 22 23 
3 9 7 24 52 
4 3 8 110 240 
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Fig 13- Effect of A. officinarum organic extract on Dictyostelium cell growth 
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Table 7 – Dictyostelium cell growth in the presence of Z. officinalis organic extract 
 
CELL NUMBER 
Days Ginger 17 
µg/mL 
 
Ginger 8.5 
µg/mL 
 
Ginger 4.2 
µg/mL 
 
DMSO Control 
 
0 5 5 5 5 
1 3 1 16 18 
2 1 24 32 23 
3 3 38 53 52 
4 3 100 220 240 
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Fig 14 – Effect of Z. officinalis organic extract on Dictyostelium cell growth 
 
 
 
 
                         
 42 
3.4 Quantitation of curcumin in turmeric fractions 
Given the promising results and therapeutic significance of turmeric (C. longa), this 
plant was chosen as the subject of further study. The C. longa extract was fractionated 
over silica gel using a binary solvent mixture of hexane and diethyl ether (see Methods 
Section 2.4) and the resulting fractions were analyzed for concentration of curcumin. 
From the data obtained, it was evident that all the turmeric fractions contained curcumin 
(ion with an m/z ratio of 367) except fraction 1. The concentration of this component in 
each fraction was determined from the calibration curve shown in Figure 15. This 
calibration curve was plotted as log of concentration versus the log of peak area of the 
selected ion chromatogram for the ion with m/z 367 and retention time 20.60 min.   
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Fig 15 - Calibration curve for curcumin 
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From the calibration curve, the concentrations of the turmeric fractions collected 
were obtained. Fraction 8 has the highest concentration of curcumin, whereas fraction 6 
has the least curcumin concentration (Figure 16). Table 8 shows the concentrations of 
curcumin in the turmeric fractions collected. Standard deviations were calculated from 
statistical analysis of the calibration curve data. 
 
 
 
Table 8 – Concentrations of curcumin from different fractions of C. longa organic extract 
including the original extract (Wt% is mg curcumin per mg dissolved solids in extract × 
100) 
 
Fraction no. Conc. (mg/mg) +/- Std. Dev. Wt% +/- Std. Dev 
1 (10% Diethyl Ether)    
2 (20% Diethyl Ether) 0.076 ± 0.021 7.6 ± 2.1 
3 (30% Diethyl Ether) 0.114 ± 0.031 11.4 ± 3.1 
4 (40% Diethyl Ether) 0.034 ± 0.009 3.4 ± 0.9 
5 (50% Diethyl Ether) 0.049 ± 0.014 5.0 ± 1.4 
6 (60% Diethyl Ether) 0.021 ± 0.006 2.1 ± 0.6 
7 (70% Diethyl Ether) 0.200 ± 0.055 20.0 ± 5.5 
8 (85% Diethyl Ether)  0.418 ± 0.117 42.0 ± 12.0 
9 (100% Diethyl Ether) 0.151 ± 0.041 15.1 ± 4.1 
Original extract 0.118 ± 0.032 12.0 ± 3.2 
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Fig 16 - Concentrations of curcumin in the turmeric extract fractions determined by 
HPLC-ESI-MS 
 
 
 
 
3.5 Other curcuminoids identified in the turmeric fractions 
After determining the curcumin concentrations in the turmeric fractions, the next 
step in this phytochemical screening would be to identify and quantify the other two 
curcuminoids present. Demethoxycurcumin (MW - 338) and bisdemethoxycurcumin 
(MW - 308) were identified in all the turmeric fractions except in fraction 1. The relative 
amounts of these curcuminoids in the various fractions were then determined based on 
the peak areas obtained for the selected ion chromatograms for the ions with m/z values 
of 337 and 307 (Figure 17 and Figure 18). Absolute quantification of these compounds 
was not possible given that standards were not commercially available. As with 
curcumin, fraction 8 has the highest concentration of the curcuminoids.  
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Fig 17 – Relative amounts of demethoxycurcumin present in the turmeric fractions 
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Fig 18 – Relative amounts of bisdemethoxycurcumin present in the turmeric fractions 
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3.6 Identification and quantitation of ar-tumerone in the turmeric fractions 
All the turmeric fractions including the original extract were analyzed for the 
presence of volatile oil constituents using positive mode HPLC-ESI-MS method. 
Significant peaks were observed only in fraction 1 and original extract samples.  Volatile 
oil components like ar-tumerone, curlone and α-tumerone were all identified with 
reference to literature
35
 (Figure 19).  
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Fig 19 – Total ion chromatogram (mass range 216-220) of the turmeric original extract 
obtained using positive mode HPLC-ESI-MS. Three volatile oil components of m/z values 
of 217 and 219 were been identified 
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The peak with an m/z value of 219 corresponds to the presence of two volatile oil 
constituents curlone and α-tumerone. Since they have the same m/z values they co-elute 
together with curlone being the first and α-tumerone the latter
35
. Since ar-tumerone was 
the compound of interest, selected ion chromatogram of this compound (MW-217) was 
plotted. Figures 20 and 21 represent the selected ion chromatograms of m/z value of 217 
for three different concentrations of fraction 1 and original extract samples. The peak 
with an m/z value of 217 represents the protonated form of neutral ar-tumerone
35
. The 
presence of this compound ar-tumerone was also confirmed by comparing the retention 
time with that of the standard ar-tumerone (Table 9). The tentative structure for 
protonated ar-tumerone compound is shown in Figures 20 and 21.  
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Fig 20 – Selected ion chromatogram of m/z value of 217 obtained using positive mode 
HPLC-ESI-MS for three different concentrations of turmeric fraction 1. a) 1mg/mL b) 
0.1mg/mL c) 0.01mg/mL. The m/z value of 217 corresponds to the mass of protonated 
form of ar-tumerone 
+ 
a) 
b) 
c) 
OH
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Fig 21 – Selected ion chromatogram of turmeric original extract obtained for an m/z 
value of 217 using positive mode HPLC-ESI-MS. Three different concentrations of a) 
1mg/mL b) 0.1mg/mL c) 0.01mg/mL were analyzed. The m/z value of 217 corresponds to 
the mass of protonated ar-tumerone 
 
 
 
Table 9 – Comparison of retention times for standard ar-tumerone and the ion with m/z 
value of 217 in the turmeric original extract 
 
Ar-tumerone  Avg. retention time Std. dev (N= 3) 
Standard  22.86 min 0.046 
Turmeric extract  22.90 min 0.098 
+ 
a) 
b) 
c) 
OH
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Figure 22 shows the MS-MS spectra of standard ar-tumerone and the peak obtained 
at a retention time of 24.62 min for turmeric original extract.  
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Fig 22 – Full scan mass spectra of (a) standard ar-tumerone (molecular weight of 216) 
and (b) the peak at a retention time of 24.62 min for turmeric original extract 
 
a) 
b) 
                         
 51 
Further, the concentration of ar-tumerone in fraction 1 and original extract was 
determined from the calibration curve of standard ar-tumerone as shown in Figure 23.  
 
 
 
y = 0.9009x + 12.459
R
2
 = 0.9997
6.5
7
7.5
8
8.5
9
9.5
10
10.5
-6.5 -6 -5.5 -5 -4.5 -4 -3.5 -3 -2.5 -2
log conc. (M)
lo
g
 p
lo
t 
p
e
a
k
 a
r
e
a
 
Fig 23 – Calibration curve for ar-tumerone obtained by plotting log of concentration vs. 
log of peak area of the selected ion chromatogram for the ion of m/z 217  
 
 
 
Based on the calibration curve data, the concentrations of ar-tumerone in fraction 1 
and turmeric original extract were calculated as shown in Table 10 and Figure 24.  
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Table 10 – Concentrations of ar-tumerone present in fraction 1 and turmeric original 
extract (wt% is mg of ar-tumerone per mg of dissolved solid extract × 100) 
 
Sample  Conc. (mg/mg) +/- Std. Dev. Wt% +/- Std. Dev 
Fraction 1 0.078  ± 0.004 7.8  ± 0.4 
Turmeric original extract 0.028  ± 0.001 2.8  ± 0.1 
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Fig 24 – Concentrations of ar-tumerone in turmeric fraction 1 and original extract 
determined by positive mode HPLC-ESI-MS 
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3.7 XTT assay results 
In the present study, the anti-proliferative activity of all the turmeric fractions 
including the original extract was evaluated using MCF-7 human breast cancer cells. This 
was accomplished by measuring the viability of cells using the XTT assay (see Methods 
Section 2.6).  
Table 11 and Figure 25 demonstrate the MCF-7 cell growth in the presence of 
different concentrations of standard curcumin for 72h duration. The relative absorbance 
at 490nm (% of vehicle control) was plotted against concentration of curcumin. Only 
viable cells metabolize the XTT reagent and produce orange colored formazan crystals 
which absorb at 490nm. Therefore, the absorbance measured is proportional to the total 
number of viable cells. Standard curcumin inhibited the MCF-7 cell proliferation in a 
dose dependent manner. The LD50 of curcumin was found to be 10µM.  
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Table 11 – MCF-7 cell growth in the presence of different concentrations of standard 
curcumin at exposure time of 72h 
 
 
Concentration (µM) Cell viability (%) ± SD 
0 100 ± 5.3 
1 74.7 ± 3.8 
3 61.2 ± 4.3 
10 51.9 ± 3.2 
30 25.0 ± 8.3 
100 22.3 ± 6.0 
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Fig 25 – Effects of different concentrations of standard curcumin on MCF-7 cell 
proliferation. Relative Absorbance (% of vehicle control) vs. Concentration of curcumin 
was plotted to determine the LD50 of curcumin which was found to be 10µM 
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Once the LD50 for curcumin against the MCF-7 cells had been determined, two 
different concentrations (3 and 30µM curcumin) of all the turmeric fractions were tested 
against MCF-7 cells using the XTT assay. The original extract and standard curcumin 
were also included in the assay. The approach used for testing these fractions was 
different than that typically employed for anti-proliferative screening of natural products. 
Typically, fractions were tested according to their dry weight, i.e. at concentrations of 2 
and 20µg/mL. This approach is very useful for identifying the most active fraction from 
amongst a set of fractions (traditional bioassay guided fraction). However, it is not 
particularly useful for situations such as this one where all of the fractions contain a 
major active component (in this case curcumin) and the desired result is information 
about whether other minor constituents contribute also to the activity. To address the 
question of whether or not constituents other than curcumin contributed to the activity of 
the extract and fractions, a novel approach was employed. Relying on the quantitative 
analysis of curcumin in the isolated fractions (Table 8), each fraction (except fraction 1) 
was normalized to the same concentration of curcumin. Because fraction 1 did not 
contain curcumin, this fraction was tested at concentrations of 4 and 40µM of ar-
tumerone, instead of as concentration of curcumin. By testing the fractions all with the 
same concentration of curcumin, it is possible to directly compare the results obtained for 
the fractions to those for standard curcumin alone at the same concentration. Any 
fractions that contain constituents that contribute (either additively or synergistically) to 
the activity of the fractions will show greater activity than curcumin alone at the same 
concentration. Any fractions that contain compounds that suppress the activity of the 
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curcumin will show less activity than curcumin alone at the same concentration. Finally, 
if the activity of the fractions is due solely to the presence of curcumin, these fractions 
will exhibit the same dose-response behavior as curcumin alone.  
The results of the MCF-7 cell assay with the individual C. longa fractions are 
shown in shown in Table 12 and Figure 26. Our data indicate that all the turmeric 
fractions and the complex turmeric extract containing curcumin exhibited similar potency 
(Figure 27). All the turmeric fractions (excluding fraction 1) including the original 
extract showed anti-proliferative activity similar to that of the standard curcumin. 
Fraction 1, which contained ar-tumerone and other volatile constituents but not curcumin, 
was found to be less effective (since the concentrations of this fraction used were 4 and 
40µM of ar-tumerone). The complex turmeric extract which contains all the 
curcuminoids and ar-tumerone showed activity similar to that of the commercially 
available curcumin compound. All these results suggest that for this assay there is no 
major synergistic or additive activity observed for the various components present in the 
turmeric samples. Our results also suggest that the overall anti-proliferative activity of the 
turmeric extract is mainly due to the presence of the major component curcumin. Fraction 
1 of the turmeric extract contained no curcumin but still had anti-proliferative activity; 
therefore, ar-tumerone and/or other volatile constituents may contribute somewhat to the 
anti-proliferative activity of C. longa. However, at the two concentrations of the complex 
extract tested, ar-tumerone was only present at concentrations of 9µM and 0.9µM. 
Therefore, its concentration was likely too low to result in significant activity.  
 
                         
 57 
Table 12 – Cell viability in the presence of different concentrations of turmeric fractions, 
original extract and standard curcumin at 72h exposure time ± SD 
 
 
% Cell viability ± SD  
3µM 30µM 
Fraction 1 91.9 ± 0.3 78.7 ± 4.9 
Fraction 2 87.1 ± 5.1 54.7 ± 0.1 
Fraction 3 84.6 ± 3.4 57.0 ± 6.5 
Fraction 4 86.7 ± 3.9 56.5 ± 7.2 
Fraction 5 83.8 ± 0.6 55.1 ± 0.4 
Fraction 6 79.8 ± 3.1 56.5 ± 9.7 
Fraction 7 85.0 ± 7.3 54.4 ± 0.8 
Fraction 8 77.4 ± 4.1 43.5 ± 11.7 
Fraction 9 86.4 ±3.8 55.8 ± 0.2 
Original extract 85.6 ± 4.6 55.7 ± 1.5 
Std curcumin 83.3 ± 9.2 55.6 ± 2.5 
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Figure 26 – MCF-7 cell viability in the presence of different concentrations of turmeric 
fractions, original extract and standard curcumin 
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Figure 27 – The percent reduction in MCF-7 cell viability at 30µM for all the turmeric 
fractions including the original turmeric extract and standard curcumin. % Cell viability 
reduction = [100 - (As – Ab)/Av×100%] where As = Absorbance of test sample well (well 
with sample+cells+media), Ab = Absorbance of blank control well (well with sample + 
media but no cells), Av = Absorbance of vehicle control well (well with cells+DMSO of 
0.5%)  
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CHAPTER IV 
CONCLUSIONS AND FUTURE SCOPE OF THIS RESEARCH 
 
 
One of the major goals of our research group is to determine how the complex 
mixtures of plant compounds contribute to the over all biological activity of the plant 
extracts. In the case of this research, an approach was developed that allowed for 
investigation of the contributions of multiple, potentially bioactive compounds to the 
anti-proliferative activity of C. longa. A simple and rapid HPLC-ESI-MS method was 
employed for the phytochemical characterization of extracts and fractions from this plant, 
and was successfully applied for both qualitative and quantitative analysis of several 
major constituents. A novel approach relying on the quantitative analysis of the fractions 
was then used to test these fractions for anti-proliferative activity against the MCF-7 
human breast cancer cell line. With this approach, it was possible to quickly determine 
that curcumin alone was primarily responsible for the overall anti-proliferative activity of 
the complex turmeric extract. Some anti-proliferative activity was also observed for a 
fraction containing ar-tumerone and other volatile constituents, but these constituents did 
not appear to contribute significantly to the overall anti-proliferative activity of the 
complex C. longa extract. While specific synergistic or additive interactions were not 
identified for C. longa in this study, the novel approach developed here could certainly be 
employed in the future for the investigation of other medicinal plants with potentially 
synergistic or additive activity.  
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This is an exciting area of research which our research group has focused on. The 
main purpose of this study was to identify the isolated turmeric fractions that have shown 
significant in vitro anti-proliferative activity. This is not the end of this research. There is 
still more investigation that needs to be done. Further studies must be designed to gain 
deeper understanding of the actual content in the isolated turmeric fractions. Fractions 
that showed significant activity will be subjected to further isolation using flash 
chromatography and/or preparatory scale HPLC. Ultimately, we seek this experimental 
approach to determine which specific fractions of turmeric are responsible for its anti-
proliferative activity. Once the isolated active components of the extract are identified, 
they have to be further studied using Dictyostelium cell model in order to gain more 
insight into the mechanism of action.  Since the exact mechanism of anti-proliferative 
activity of curcumin is not clearly understood, the outcomes of this Dictyostelium cell 
assay would prove highly beneficial.  
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